Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs

FDA, “Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products,” in Services DoHaH, ed. Washington, D.C., 2004, available at <http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf>(last visited December 5, 2014)

Left to their own devices: “Medtronic and the Woes of America's Medical-Technology Industry,” The Economist, September 11, 2011, available at <http://www.economist.com/node/21528644>(last visited December 5, 2014).

Avorn J. Kesselheim A. , “The NIH Translational Research Center Might Trade Public Risk for Private Reward,” Nature Medicine 17, no. 10(2011): 1176.

Munos B. H. Chin W. W. , “How to Revive Breakthrough Innovation in the Pharmaceutical Industry,” Science Translational Medicine 3, no. 89(2011): 9cm16.

Arrowsmith J. , “Trial Watch: Phase II Failures: 2008–2010,” Nature Reviews Drug Discovery 10, no. 5(May 2011): 328–329.

PricewaterhouseCoopers, MoneyTree Report, Vol 2013, available at <http://www.pwcmoneytree.com/HistoricTrends/>.

Juliano R. , “Pharmaceutical Innovation and Public Policy: The Case for a New Strategy for Drug Discovery and Development,” Science and Public Policy 40, no. 3(2013): 393–405.

Paul S. M. Mytelka D. S. Dunwiddie C. T. , “How to Improve R&D Productivity: The Pharmaceutical Industry's Grand Challenge,” Nature Reviews Drug Discovery 9, no. 3(2010): 203–214.

Chabner B. A. Roberts T. G. Jr. , “Timeline: Chemotherapy and the War on Cancer,” Nature Reviews Cancer 5, no. 1(2005): 65–72.

Cutler D. M. McClellan M. , “Is Technological Change in Medicine Worth It?” Health Affairs (Millwood) 20, no. 5(2001): 11–29.

Clardy J. Fischbach M. A. Walsh C. T. , “New Antibiotics from Bacterial Natural Products,” Nature Biotechnology 24, no. 12(2006): 1541–1550.

Hanna K. E. Manning F. J. Bouxsein P. Pope A. , Innovation and Invention in Medical Devices: Workshop Summary, Institute of Medicine (Washington, D.C.: National Academies Press, 2001).

Krucoff M. W. Brindis R. G. Hodgson P. K. Mack M. J. Holmes D. R. Jr. , “Medical Device Innovation: Prospective Solutions for an Ecosystem in Crisis: Adding a Professional Society Perspective,” JACC: Cardiovascular Interventions 5, no. 7(2012): 790–796.

Ubl S. J. , “The Medical Device Excise Tax – Before It Begins?” New England Journal of Medicine 369, no. 10(2013): 984.

Staff C. , “Internal Memorandum: Ten Bills to Fix FDA's Medical Device Regulation: Saving American Jobs and Saving American Patients,” Commerce HoRCoEa, Washington, D.C., 2011.

Sherman R. E. Li J. Shapley S. Robb M. Woodcock J. , “Expediting Drug Development: The FDA's New ‘Breakthrough Therapy’ Designation,” New England Journal of Medicine 369, no. 20(2013): 1877–1880.

See Kesselheim and Avorn, supra note 3.

Drucker P. F. , “The Discipline of Innovation,” Harvard Business Review 63, no. 3(1985): 67–72.

Kesselheim A. S. Avorn J. , “The Most Transformative Drugs of the past 25 Years: A Survey of Physicians,” Nature Reviews Drug Discovery 12, no. 6(2013): 425–431.

Constas M. A. , “Qualitative Analysis as a Public Event: The Documentation of Category Development Procedures,” American Educational Research Journal 29, no. 2(1992): 253–266.

Bradley E. H. Holmboe E. S. Mattera J. A. Roumanis S. A. Radford M. J. Krumholz H. M. , “A Qualitative Study of Increasing Beta-Blocker Use after Myocardial Infarction: Why Do Some Hospitals Succeed?” JAMA 285, no. 20(2001): 2604–2611.

Willms D. G. Best J. A. Taylor D. W. , “A Systematic Approach for Using Qualitative Methods in Primary Prevention Research,” Medical Anthropology Quarterly 4, no. 4(1990): 391–409.

Drucker P. F. , “The Discipline of Innovation,” Harvard Business Review 63, no. 3(1985): 67–72.

Schmookler J. , Invention and Economic Growth (Cambridge, MA: Harvard University Press, 1966).

Shane S. Venkataraman S. , “The Promise of Entrepreneurship as a Field of Research,” Academy of Management Review 25, no. 1(2000): 217–226.

Sarason Y. Dean T. Dillard J. R. , “Entrepreneurship as the Nexus of Individual and Opportunity: A Structuration View,” Journal of Business Venturing 21, no. 3(2006): 286–305.

Eichler H. G. Bloechl-Daum B. Brasseur D. , “The Risks of Risk Aversion in Drug Regulation,” Nature Reviews Drug Discovery 12, no. 12(2013): 907–916.

Kesselheim A. S. Xu S. Avorn J. , “Clinicians' Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation,” PloS One 9, no. 2(2014): e88664.

Tralau-Stewart C. J. Wyatt C. A. Kleyn D. E. Ayad A. , “Drug Discovery: New Models for Industry-Academic Partnerships,” Drug Discovery Today 14, nos. 1–2(2009): 95–101.

Melese T. Lin S. M. Chang J. L. Cohen N. H. , “Open Innovation Networks between Academia and Industry: An Imperative for Breakthrough Therapies,” Nature Medicine 15, no. 5(2009): 502–507.

Swinney D. C. Anthony J. , “How Were New Medicines Discovered?” Nature Reviews Drug Discovery 10, no. 7(2011): 507–519.

Agarwal P. Searls D. B. , “Can Literature Analysis Identify Innovation Drivers in Drug Discovery?” Nature Reviews Drug Discovery 8, no. 11(2009): 865–878.

Zinner D. E. Bolcic-Jankovic D. Clarridge B. Blumenthal D. Campbell E. G. , “Participation of Academic Scientists in Relationships with Industry,” Health Affairs (Millwood) 28, no. 6(2009): 1814–1825.

Feldman M. Desrochers P. , “Truth for Its Own Sake: Academic Culture and Technology Transfer at Johns Hopkins University,” Minerva 42, no. 2(2004): 105–126.

Jong S. , “How Organizational Structures in Science Shape Spin-Off Firms: The Biochemistry Departments of Berkeley, Stanford, and UCSF and the Birth of the Biotech Industry,” Industrial and Corporate Change 115, no. 2(2006): 251–283.

See Melese , supra note 23.

Blumenthal D. Campbell E. G. Causino N. Louis K. S. , “Participation of Life-Science Faculty in Research Relationships with Industry,” New England Journal of Medicine 335, no. 23(1996): 1734–1739.

Bok D. C. , Beyond the Ivory Tower: Social Responsibilities of the Modern University (Cambridge, MA: Harvard University Press, 1982).

Krimsky S. , Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? (Lanham, Maryland: Rowman & Littlefiel, 2003).

Azoulay P. Ding W. Stuart T. , The Impact of Academic Patenting on the Rate, Quality and Direction of (Public) Research Output,” Journal of Industrial Economics 57, no. 4(2009): 637–676.

Grimaldi R. Kenney M. Siegel D. S. Wright M. , “30 Years after Bayh-Dole: Reassessing Academic Entrepreneurship,” Research Policy 40, no. 8(2011): 1045–1057.

Kenney M. Patton D. , “Reconsidering the Bayh-Dole Act and the Current University Invention Ownership Model,” Research Policy 38, no. 9(2009): 1407–1422.

Swamidass P. M. Vulasa V. , “Why University Inventions Rarely Produce Income? Bottlenecks in University Technology Transfer,” Journal of Technology Transfer 34, no. 4(2009): 343–363.

See Kenney Patton , supra note 33.

Innes C. , “Best Practices in Transforming Research into Innovation: Creative Approaches to the Bayh-Dole Act,” U.S. House of Representatives, Committee on Science, Space, and Technology, Subcommittee on Technology and Innovation, 2012.

Xu S. Avorn J. Kesselheim A. S. , “Origins of Medical Innovation: The Case of Coronary Artery Stents,” Circulation: Cardiovascular Quality and Outcomes 5, no. 6(2012): 743–749.

Scannell J. W. Blanckley A. Boldon H. Warrington B. , “Diagnosing the Decline in Pharmaceutical R&D Efficiency,” Nature Reviews Drug Discovery 11, no. 3(2012): 191–200.

Fernandez J. M. Stein R. M. Lo A. W. , “Commercializing Biomedical Research through Securitization Techniques,” Nature Biotechnology 30, no. 10(2012): 964–975.

See Munos Chin , supra note 3.

Paulsen E. Altmire J. , “New Tax Will Hurt Medical Device Innovation,” The Hill's Congress Blog vol. 2013, 2012.

Bloom J. Torreele E. , “Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?” Wall Street Journal, January 23, 2012.

See Staff, supra note 11.

Ebersole T. J. Guthrie M. C. Goldstein J. A. , “Patent Pools and Standard Setting in Diagnostic Genetics,” Nature Biotechnology 23, no. 8(2005): 937–938.

Hunter J. Stephens S. , “Is Open Innovation the Way Forward for Big Pharma?” Nature Reviews Drug Discovery 9, no. 2(2010): 87–88.